CN115448907A - Compound for treating peptic ulcer, intermediate and preparation method - Google Patents

Compound for treating peptic ulcer, intermediate and preparation method Download PDF

Info

Publication number
CN115448907A
CN115448907A CN202211243523.XA CN202211243523A CN115448907A CN 115448907 A CN115448907 A CN 115448907A CN 202211243523 A CN202211243523 A CN 202211243523A CN 115448907 A CN115448907 A CN 115448907A
Authority
CN
China
Prior art keywords
compound
reaction
stirring
room temperature
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202211243523.XA
Other languages
Chinese (zh)
Other versions
CN115448907B (en
Inventor
吴彪
朱天泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sailong Pharmaceutical Group Co ltd
Original Assignee
Sailong Pharmaceutical Group Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sailong Pharmaceutical Group Co ltd filed Critical Sailong Pharmaceutical Group Co ltd
Priority to CN202211243523.XA priority Critical patent/CN115448907B/en
Publication of CN115448907A publication Critical patent/CN115448907A/en
Application granted granted Critical
Publication of CN115448907B publication Critical patent/CN115448907B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention provides a compound for treating peptic ulcer, an intermediate and a preparation method thereof. The present invention provides the following reaction scheme, wherein the chemical name of the compound I is 1- [5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrole-3-yl]-N-propyleneglycolmethylamine monofumaric acid, compound II ethyl 5- (2-fluorophenyl) -1H-pyrrole-3-carboxylate, compound III pyridine-3-sulfonyl chloride, compound IV ethyl 5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrole-3-carboxylate, compound V5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrole-3-carboxamide, compound VI 5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrole-3-methylamine, compound VII 1- [5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrol-3-yl ] -1H-pyrrol-3-yl]The N-propylene glycol methylamine adopts a new synthetic route, has low price and easily-available raw materials in the marketObtaining; compared with the prior synthetic route, the reagent used in the reaction is green and environment-friendly, the reaction condition is mild, the selectivity is good, and the post-treatment is simpler.

Description

Compound for treating peptic ulcer, intermediate and preparation method
Technical Field
The invention belongs to the field of medicines, and particularly relates to a compound for treating peptic ulcer, an intermediate and a preparation method thereof.
Background
Gastric Acid Related Diseases (ARDs) are upper gastrointestinal diseases in which gastric acid is closely related to pathogenesis, and comprise gastroesophageal reflux disease, dyspepsia, gastrointestinal ulcer, gastritis, duodenitis and gastrointestinal diseases caused by some anti-inflammatory drugs. The incidence of ARDs is on the rise year by year worldwide. In China, ARDS has become one of the major diseases, and seriously affects the quality of life of patients. Proton Pump Inhibitors (PPIs) have been widely used clinically in the treatment of ARDs, and are the main therapeutic drugs for such diseases.
As a potassium ion competitive acid blocker (P-CAB), vonoprazan fumarate has the following advantages compared with conventional irreversible proton pump inhibitors (such as omeprazole, pantoprazole, and the like): (1) conventional proton pump inhibitors form covalent bonds with the cysteine residues of H +/K + -atpase, irreversibly inhibiting enzymatic activity; whereas TAK438 is reversible, is a potassium competitive acid blocker, and has a faster onset of action since it does not require strong acid-dependent activation transformation. (2) Has good stability under acidic condition, and can be highly enriched in gastric acid tubule wall cells to take effect. (3) The occurrence of acid breakthrough at night can be obviously reduced in clinical application.
However, since vonoprazan fumarate is poor in water solubility, it cannot be formulated into an injection, and it can be formulated into only an oral solid preparation, which generally takes several hours to exhibit therapeutic effects, and is disadvantageous for emergency administration.
At present, aiming at the problem of poor water solubility of vonoprazan fumarate, the known technology reports a novel compound with good water solubility, and the structural formula is shown as I:
Figure BDA0003878421580000021
the compound has obvious effect of inhibiting gastric mucosa injury on the basis of water solubility. Patent CN112812099B discloses a synthesis method of compound I, which route is as follows:
Figure BDA0003878421580000022
the starting material (compound 1) used in the method is expensive, and the world patent WO2007026916 discloses a synthetic method of the compound 1, and the route is as follows:
Figure BDA0003878421580000023
according to the route reported in patent WO2007026916, compound 1 needs to be reduced into alcohol through ester group, the alcohol is oxidized into aldehyde group, expensive and air-sensitive reagent diisobutylaluminum hydride (DIBAL-H) is used in the process of reducing the ester group, and the reaction needs to be carried out under the condition of-78 ℃, and the conditions are harsh. Diisobutylaluminum hydride reagent is highly flammable and requires ultra low temperature for reaction, thus not suitable for industrial production operation.
Disclosure of Invention
In order to overcome the technical defects of the existing synthesis process of the compound I, a new synthesis process is urgently needed to be developed, and a compound which is low in price and easy to obtain in the market is used as a raw material; the reagent used in the reaction is green and environment-friendly, the reaction condition is milder, the selectivity is good, and the post-treatment is simpler.
In order to achieve the above object, the present invention provides a novel preparation method of compound I, which comprises four steps of reaction and one step of salt formation, for a total of five steps. The method comprises the following specific steps:
Figure BDA0003878421580000031
Figure BDA0003878421580000041
the solvent used in the first step is one or more of acetonitrile, acetone, butanone, tetrahydrofuran, dioxane, N-dimethylformamide and N, N-dimethylacetamide;
the alkaline reagent selected in the first step is one or more of diisopropylethylamine, triethylamine, sodium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and sodium methoxide;
the solvent selected in the second step reaction is one or more of methanol, ethanol, isopropanol, acetonitrile, tetrahydrofuran, dioxane, N-dimethylformamide and N, N-dimethylacetamide;
the second step reaction selects one or more of diisopropylethylamine, triethylamine, sodium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and sodium methoxide as alkaline reagents;
the reaction reagents selected in the second step of reaction comprise: one or more of ammonia water, ammonia gas, ammonium chloride and ammonium acetate;
the solvent selected in the third step is one or more of tetrahydrofuran, toluene, methyl tert-butyl ether, isopropyl ether, dioxane, N-dimethylformamide and N, N-dimethylacetamide;
the reducing agent selected in the third step is one or more of sodium borohydride, potassium borohydride, sodium cyanoborohydride and lithium aluminum hydride;
the Lewis acid selected for the reaction in the third step is one or more of aluminum trichloride, zinc chloride, boron trifluoride and sulfuric acid;
the solvent selected in the fourth step is one or more of methanol, ethanol, isopropanol, acetonitrile, acetone, tetrahydrofuran, toluene, methyl tert-butyl ether, isopropyl ether, dioxane, N-dimethylformamide and N, N-dimethylacetamide;
the reaction reagent selected in the fourth step is one or more of 3-chlorine-1, 2-propylene glycol, 3-bromine-1, 2-propylene glycol and 3-iodine-1, 2-propylene glycol;
the alkaline reagents selected in the fourth step of reaction comprise: one or more of diisopropylethylamine, triethylamine, sodium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and sodium methoxide.
The method comprises the following steps:
(1) Putting a compound II and a compound III into a solvent, adding an alkaline reagent, and adding a catalyst DMAP (dimethyl formamide) to perform a catalytic reaction to obtain a compound IV; preferably, the selected solvent is acetonitrile and the selected basic agent is DIEA; preferably, the catalytic reaction temperature is usually 0 to 100 ℃, further preferably 10 ℃ to 50 ℃. (Compound II,5- (2-fluorophenyl) -1H-pyrrole-3-carboxylic acid ethyl ester, commercially available as raw material, available from Saiboda chemical Co., ltd., lot No. SBD 220301.)
Figure BDA0003878421580000051
(2) Putting the compound IV into a solvent, adding an alkaline reagent, and carrying out urethane exchange reaction with a reaction reagent to obtain a compound V; preferably, the solvent is methanol, the alkaline reagent is sodium methoxide, and the reaction reagent is ammonia water; preferably, the urethane exchange reaction temperature is usually 0 to 100 ℃ and more preferably 10 to 50 ℃.
Figure BDA0003878421580000061
(3) The compound V is subjected to reduction reaction in a non-aqueous solvent under the action of a metal reducing agent and Lewis acid to prepare a compound VI; preferably, the reduction reaction temperature is usually 0 to 150 ℃, and more preferably 10 ℃ to 80 ℃; the reducing agent molar equivalent is: 0.25 to 10 molar equivalents, preferably 1 to 2 molar equivalents; lewis acid molar equivalents are: 0.25 to 10 molar equivalents, preferably 1 to 2 molar equivalents.
Figure BDA0003878421580000062
(4) Putting a compound VI and a reaction reagent into a solvent, adding an alkaline reagent, and carrying out condensation reaction to obtain a compound VII, wherein preferably, the solvent is methanol, the reaction reagent is 3-chloro-1, 2-propanediol, and the alkaline reagent is sodium hydroxide; preferably, the condensation reaction temperature is usually 0 to 100 ℃ and more preferably 10 to 50 ℃. Adding N, N-dimethylacetamide into the compound VII, stirring for dissolving, adding fumaric acid, stirring for dissolving, adding ethyl acetate, stirring for crystallizing at room temperature, filtering, and drying under reduced pressure to obtain the compound I.
Figure BDA0003878421580000071
The invention has the advantages that a new synthetic route is adopted, 5- (2-fluorophenyl) -1H-pyrrole-3-ethyl formate is selected, diisobutyl aluminum hydride (DIBAL-H) is not needed, the price is low, and raw materials are easily available in the market; compared with the prior synthetic route, the reagents used in the reaction are more environment-friendly, the reaction conditions are milder, the selectivity is good, and the post-treatment is simpler.
Detailed Description
EXAMPLE 1 Synthesis of ethyl 5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrole-3-carboxylate (Compound IV)
Figure BDA0003878421580000072
To the reaction flask were added 30g of ethyl 5- (2-fluorophenyl) -1H-pyrrole-3-carboxylate (Compound II), 100ml of acetonitrile (CH) 3 CN), 29g of N, N-Diisopropylethylamine (DIEA) and 4g of 4-Dimethylaminopyridine (DMAP), adding 35g of pyridine-3-sulfonyl chloride (compound III) at room temperature, stirring at room temperature for reaction for 30min, adding water to quench the reaction after the reaction is finished, regulating the pH to 5 by using hydrochloric acid, cooling to room temperature, stirring for crystallization, filtering, and drying under reduced pressure to obtain a compound IV, wherein the compound IV is 44g of off-white crystalline powder, and the yield is 84%.
1H-NMR(CDCl 3 )δ：1.35(3H，t，J＝7.2Hz)，4.30(2H，q，J＝7.2Hz)，6.69(1H，d，J＝1.8Hz)，7.05(1H，m)，7.20(2H，m)，7.40(1H，m)，7.50(1H，m)，7.7(1H，m)，8.]5(1H，d，J＝1.8Hz)，8.59(1H，d，J＝2.2Hz)，8.81(1H，m)。
EXAMPLE 2 Synthesis of 5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrole-3-carboxamide (Compound V)
Figure BDA0003878421580000081
Adding 40g of compound IV, 200ml of methanol and 16ml of 25% ammonia water into a reaction bottle, cooling to below 20 ℃, dropwise adding 20ml of 30% sodium methoxide methanol solution, controlling the temperature to be below 30 ℃ in the dropwise adding process, stirring at room temperature for reaction for 5 hours after the dropwise adding is finished.
After the reaction is finished, regulating the pH value to 6-7 by using hydrochloric acid, supplementing 200ml of purified water, cooling to 0-10 ℃, stirring and crystallizing for 6h, separating out a white-like solid, filtering, and drying under reduced pressure to obtain 34.3g of a compound V, wherein the yield is 93 percent, and the purity is 95 percent.
Example 3 Synthesis of 5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrole-3-methanamine (Compound VI)
Figure BDA0003878421580000082
Under the protection of nitrogen, 30g of compound V and 300ml of tetrahydrofuran are added into a reaction flask, then 3.6g of sodium borohydride and 12.6g of boron trifluoride diethyl etherate are added in portions, the temperature is increased to reflux, and the reaction is stirred for 6 hours.
After the reaction is finished, cooling to room temperature, regulating the pH value to 2-3 by hydrochloric acid, cooling to 0-10 ℃, stirring for crystallization overnight, filtering, stirring and pulping a filter cake by 100ml of ethyl acetate at room temperature for 1h, filtering, and drying the filter cake under reduced pressure to obtain a compound VI which is a white-like solid 28.4g, the yield is 89%, and the purity is 98%.
1H-NMR(MeOD)δ：8.76(1H，dd，J＝4.9，1.6Hz)，8.51(1H，dd，J＝2.4，0.8Hz)，7.87(1H，m)，7.57-7.39(3H，m)，7.23-7.02(3H，m)，6.32(1H，d，J＝1.8Hz)，3.90(2H，d，J＝1.0Hz).
EXAMPLE 4 Synthesis of 1- [5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrol-3-yl ] -N-propyleneglycolmethanaminemethanemethanesulfonic acid (Compound I)
Figure BDA0003878421580000091
(1) At room temperature, 25g of compound VI, 34ml of 2N sodium hydroxide solution and 200ml of methanol are added into a reaction bottle, 9g of 3-chloro-1, 2-propanediol is added, the temperature is raised to 40-50 ℃, and the reaction is stirred for 5 hours. After the reaction is finished, regulating the pH value to 10 by hydrochloric acid, decompressing and concentrating to remove methanol, adding 200ml of ethyl acetate and 200ml of purified water for extraction, washing an organic phase by water, decompressing and concentrating to obtain an oily substance, namely 1- [5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrole-3-yl ] -N-propylene glycol methylamine (a compound VII); compound VII is free state of 1- [5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrole-3-yl ] -N-propylene glycol methylamine monofumaric acid (compound I)
(2) To compound VII was added 100ml of N, N-dimethylacetamide, and dissolved with stirring, 7.5g of fumaric acid was added and dissolved with stirring, and 100ml of ethyl acetate was added, followed by crystallization with stirring at room temperature for 1H, filtration and drying under reduced pressure to give 1- [5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrol-3-yl ] -N-propanediol methylamine monofumaric acid (compound I) as a white solid (32 g), yield 91% and purity 99%.
LC-MS：[M+1] + It was 405.8.
1H-NMR(DMSO)δ：δ8.90(1H，dd，J＝1.2，4.8Hz)、δ8.57(1H，d，J＝2.1Hz)、7.88(1H，m)、7.78(1H，s)、7.61(1H，dd，J＝4.9，8.1Hz)、7.51(1H，m)、7.22(2H，m)、7.10(1H，m)、6.56(1H，d，J＝1.6Hz)、6.54(2H，s)、4.04(2H，s)、3.88(1H，m)、4.45(1H，m)、4.35(1H，m)、3.00(1H，m)、2.79(1H，m)。
Although the invention has been described in detail hereinabove by way of general description, specific embodiments and experiments, it will be apparent to those skilled in the art that modifications and improvements can be made thereto without departing from the scope of the invention. Accordingly, it is intended that all such modifications and alterations be included within the scope of this invention as defined in the appended claims.

Claims (10)

1. Process for the preparation of compound I, characterized in that said compound I is prepared according to the following reaction scheme:
Figure FDA0003878421570000011
wherein compound I is chemically known as 1- [5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrol-3-yl ] -N-propanediol methylamine monofumaric acid, compound II is chemically known as ethyl 5- (2-fluorophenyl) -1H-pyrrole-3-carboxylate, compound III is chemically known as pyridine-3-sulfonyl chloride, compound IV is chemically known as ethyl 5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrole-3-carboxylate, compound V is chemically known as 5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrole-3-carboxamide, compound VI is chemically known as 5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrole-3-methylamine, compound VII is chemically known as 1- [5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1H-pyrrol-3-yl ] -N-propanediol methylamine;
the solvent selected in the first step reaction is one or more of acetonitrile, acetone, butanone, tetrahydrofuran, dioxane, N-dimethylformamide and N, N-dimethylacetamide;
the alkaline reagent selected in the first step is one or more of diisopropylethylamine, triethylamine, sodium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and sodium methoxide;
the solvent selected in the second step reaction is one or more of methanol, ethanol, isopropanol, acetonitrile, tetrahydrofuran, dioxane, N-dimethylformamide and N, N-dimethylacetamide;
the alkaline reagent selected in the second step is one or more of diisopropylethylamine, triethylamine, sodium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and sodium methoxide;
the reaction reagents selected in the second step of reaction comprise: one or more of ammonia water, ammonia gas, ammonium chloride and ammonium acetate;
the solvent selected in the third step is one or more of tetrahydrofuran, toluene, methyl tert-butyl ether, isopropyl ether, dioxane, N-dimethylformamide and N, N-dimethylacetamide;
the reducing agent selected in the third step is one or more of sodium borohydride, potassium borohydride, sodium cyanoborohydride and lithium aluminum hydride;
the Lewis acid selected for the reaction in the third step is one or more of aluminum trichloride, zinc chloride, boron trifluoride and sulfuric acid;
the solvent used in the fourth step is one or more of methanol, ethanol, isopropanol, acetonitrile, acetone, tetrahydrofuran, toluene, methyl tert-butyl ether, isopropyl ether, dioxane, N-dimethylformamide and N, N-dimethylacetamide;
the reaction reagent selected in the fourth step is one or more of 3-chloro-1, 2-propanediol, 3-bromo-1, 2-propanediol and 3-iodo-1, 2-propanediol;
the alkaline reagent selected in the fourth step of reaction comprises: one or more of diisopropylethylamine, triethylamine, sodium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and sodium methoxide.
2. The preparation method of the compound I according to claim 1, wherein in the first step of the reaction for preparing the compound IV, the compound II and the compound III are put into a solvent, an alkaline reagent is added, and a catalyst DMAP is added for catalytic reaction to obtain the compound IV; preferably, the selected solvent is acetonitrile and the selected basic agent is DIFA; preferably, the catalytic reaction temperature is usually 0 to 100 ℃, further preferably 10 ℃ to 50 ℃.
3. The method for preparing the compound I according to claim 1, wherein the second step of the reaction for preparing the compound V is prepared by putting the compound IV into a solvent, adding a basic reagent, and performing urethane exchange reaction with the reaction reagent; preferably, the solvent is methanol, the alkaline reagent is sodium methoxide, and the reaction reagent is ammonia water; preferably, the urethane exchange reaction temperature is usually 0 to 100 ℃ and more preferably 10 to 50 ℃.
4. The process for preparing compound I according to claim 1, wherein compound VI is prepared by the reduction of compound V in a non-aqueous solvent with a metal reducing agent in combination with a Lewis acid. Preferably, the reduction reaction temperature is usually 0 to 150 ℃, and more preferably 10 ℃ to 80 ℃.
5. The process for preparing the compound I according to claim 1, wherein in the fourth reaction step for preparing the compound VII, the compound VI and a reaction reagent are put into a solvent, a basic reagent is added, and the condensation reaction is carried out to generate the compound VII, preferably, the solvent is methanol, the reaction reagent is 3-chloro-1, 2-propanediol, and the basic reagent is sodium hydroxide; preferably, the condensation reaction temperature is usually 0 to 100 ℃ and more preferably 10 ℃ to 50 ℃.
In the fifth step of reaction for preparing the compound I, N-dimethylacetamide is added into a compound VII, stirred and dissolved, fumaric acid is added, stirred and dissolved, ethyl acetate is added, stirred and crystallized at room temperature, filtered, and dried under reduced pressure to obtain the compound I.
6. The process for preparing compound I according to claim 1, wherein the first reaction step is: to the reaction flask were added ethyl 5- (2-fluorophenyl) -1H-pyrrole-3-carboxylate (Compound II), acetonitrile (CH) 3 CN), N-Diisopropylethylamine (DIFA) and 4-Dimethylaminopyridine (DMAP), adding pyridine-3-sulfonyl chloride (compound III) at room temperature, stirring for reaction at room temperature, adding water for quenching reaction after the reaction is finished, adjusting pH with hydrochloric acid, cooling to room temperature, stirring for crystallization, filtering, and drying under reduced pressure to obtain a compound IV;
the second step of reaction is as follows: adding a compound IV, methanol and 25% ammonia water into a reaction bottle, cooling to below 20 ℃, dropwise adding a methanol solution of 30% sodium methoxide, controlling the temperature to be below 30 ℃ in the dropwise adding process, stirring and reacting at room temperature after dropwise adding, adjusting the pH value to 6-7 by using hydrochloric acid after reaction, supplementing purified water, cooling to 0-10 ℃, stirring and crystallizing, separating out a white-like solid, filtering, and drying under reduced pressure to obtain a compound V;
the third step of reaction is as follows: adding a compound V and tetrahydrofuran into a reaction bottle under the protection of nitrogen, then adding sodium borohydride and boron trifluoride diethyl etherate in batches, heating to reflux, stirring for reaction, cooling to room temperature after the reaction is finished, adjusting the pH to 2-3 with hydrochloric acid, cooling to 0-10 ℃, stirring for crystallization overnight, filtering, stirring and pulping a filter cake with ethyl acetate at room temperature, filtering, and drying the filter cake under reduced pressure to obtain a compound VI;
the fourth reaction step is as follows: adding the compound VI, 2N sodium hydroxide solution and methanol into a reaction bottle at room temperature, adding 3-chloro-1, 2-propanediol, heating to 40-50 ℃, and stirring for reaction. After the reaction is finished, regulating the pH value by using hydrochloric acid, decompressing and concentrating to remove methanol, adding ethyl acetate and purified water for extraction, washing an organic phase by using water, decompressing and concentrating to obtain a compound VII;
the fifth step reaction is: adding N, N-dimethylacetamide into the compound VII, stirring for dissolving, adding fumaric acid, stirring for dissolving, adding ethyl acetate, stirring at room temperature for crystallizing, filtering, and drying under reduced pressure to obtain the compound I.
7. An intermediate useful in the preparation of compound I according to any one of claims 1 to 6, which is compound IV, as synthesized by the following method:
to the reaction flask were added ethyl 5- (2-fluorophenyl) -1H-pyrrole-3-carboxylate (Compound II), acetonitrile (CH) 3 CN), N-Diisopropylethylamine (DIEA) and 4-Dimethylaminopyridine (DMAP), adding pyridine-3-sulfonyl chloride (compound III) at room temperature, stirring for reaction at room temperature, adding water for quenching reaction after the reaction is finished, adjusting pH value by hydrochloric acid, cooling to room temperature, stirring for crystallization, filtering, and drying under reduced pressure to obtain a compound IV.
8. A synthetic method for preparing an intermediate as claimed in any one of claims 1 to 6, compound V, is as follows:
adding the compound IV, methanol and 25% ammonia water into a reaction bottle, cooling to below 20 ℃, dropwise adding 30% sodium methoxide methanol solution, controlling the temperature to be below 30 ℃ in the dropwise adding process, stirring at room temperature for reaction after the dropwise adding is finished, adjusting the pH value to 6-7 by hydrochloric acid after the reaction is finished, supplementing purified water, cooling to 0-10 ℃, stirring for crystallization, separating out off a white-like solid, filtering, and drying under reduced pressure to obtain the compound V.
9. A synthetic method for preparing an intermediate according to any one of claims 1 to 6, compound VI, is as follows:
adding a compound V and tetrahydrofuran into a reaction bottle under the protection of nitrogen, then adding sodium borohydride and boron trifluoride diethyl etherate in batches, heating to reflux, stirring for reaction, cooling to room temperature after the reaction is finished, adjusting the pH to 2-3 with hydrochloric acid, cooling to 0-10 ℃, stirring for crystallization overnight, filtering, stirring and pulping a filter cake with ethyl acetate at room temperature, filtering, and drying the filter cake under reduced pressure to obtain a compound VI.
10. Compound I, prepared by the process of any one of claims 1 to 6.
CN202211243523.XA 2022-10-08 2022-10-08 Compound for treating peptic ulcer, intermediate and preparation method thereof Active CN115448907B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211243523.XA CN115448907B (en) 2022-10-08 2022-10-08 Compound for treating peptic ulcer, intermediate and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211243523.XA CN115448907B (en) 2022-10-08 2022-10-08 Compound for treating peptic ulcer, intermediate and preparation method thereof

Publications (2)

Publication Number Publication Date
CN115448907A true CN115448907A (en) 2022-12-09
CN115448907B CN115448907B (en) 2024-01-12

Family

ID=84308380

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211243523.XA Active CN115448907B (en) 2022-10-08 2022-10-08 Compound for treating peptic ulcer, intermediate and preparation method thereof

Country Status (1)

Country Link
CN (1) CN115448907B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003383A (en) * 2022-12-30 2023-04-25 山东铂源药业股份有限公司 Preparation method of voronoi

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102212040A (en) * 2010-04-07 2011-10-12 上海奥博生物医药技术有限公司 Novel preparation method for chiral 2-hydroxymethyl morpholine compounds
CN107915720A (en) * 2016-10-08 2018-04-17 常州市第四制药厂有限公司 The new preparation process of Wo Nuolazan
CN112812099A (en) * 2021-01-19 2021-05-18 珠海赛隆药业股份有限公司 Compound for treating peptic ulcer and preparation method and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102212040A (en) * 2010-04-07 2011-10-12 上海奥博生物医药技术有限公司 Novel preparation method for chiral 2-hydroxymethyl morpholine compounds
CN107915720A (en) * 2016-10-08 2018-04-17 常州市第四制药厂有限公司 The new preparation process of Wo Nuolazan
CN112812099A (en) * 2021-01-19 2021-05-18 珠海赛隆药业股份有限公司 Compound for treating peptic ulcer and preparation method and application thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003383A (en) * 2022-12-30 2023-04-25 山东铂源药业股份有限公司 Preparation method of voronoi

Also Published As

Publication number Publication date
CN115448907B (en) 2024-01-12

Similar Documents

Publication Publication Date Title
CN107915720B (en) Novel preparation method of Vonoprazan
KR102233455B1 (en) Method for preparation of intermediate of 4-methoxypyrrole derivative
CN115448907B (en) Compound for treating peptic ulcer, intermediate and preparation method thereof
CN111808034B (en) Method for synthesizing 1,2, 4-triazole-3-methyl carboxylate
CN109206317B (en) Preparation process of amantadine nitrate derivative
CN112300212A (en) Use of borane-pyridine complexes for the preparation of NK-1 receptor antagonists
KR101123292B1 (en) Process for Preparation of Montelukast Sodium Salt
CN109503513B (en) One-pot synthesis method of febuxostat intermediate
KR100712003B1 (en) A process for producing phenserine and its analog
CN115232107A (en) Preparation method of high-purity Voranolan fumarate
CN112707889B (en) Synthesis method of lansoprazole
CN113214223B (en) Preparation method of Voranolan fumarate impurity
JP2002506862A (en) Chemical process for preparing sulfinyl derivatives by oxidation of the corresponding thio derivatives with perborates
CN114539216A (en) Preparation method of Vonoprazan
CN112094219B (en) Method for preparing intermediate of potassium ion competitive retarder
CN103145692A (en) Preparation method of 4, 5-dihydro-6H-cyclopenta[b]thiophene-6-ketone
CN113354623B (en) Preparation method of ilaprazole key intermediate 5- (1H-pyrrole-1-yl) -2-mercaptobenzimidazole
CN111892527B (en) Indole derivatives and synthesis method thereof
CN115286568A (en) Preparation method of 2-hydroxy-4-trifluoromethylpyridine
CN116283904A (en) Preparation method of 3- (2-pyridyl) -5, 6-diphenyl-1, 2, 4-triazine
CN110172038B (en) Process for preparing analgin magnesium by one-pot method
WO2009145368A1 (en) Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent
CN117603189A (en) Preparation method of vonoprazan fumarate
CN115974842A (en) Preparation method of pyrroltinib
CN113563318A (en) Synthesis method of engagliflozin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant